Pozanicline Hydrochloride(Pozanicline Hydrochloride) - 药物靶点：CHRNA7 x nAChR α4/β2/α5 x nAChRα3&β4_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Pozanicline、Pozanicline Tartrate

+ [2]

靶点

CHRNA7 x nAChR α4/β2/α5 x nAChRα3&β4

作用方式

激动剂、拮抗剂

作用机制

nAChR α4/β2/α5激动剂(烟碱性胆碱能受体α4/β2/α5复合体激动剂)、α3β4 receptor拮抗剂(神经性乙酰胆碱受体蛋白α3/β4复合体拮抗剂)、α7 receptor激动剂(神经性乙酰胆碱受体蛋白α-7亚基激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症-

非在研适应症

阿尔茨海默症注意缺陷障碍伴多动

原研机构

AbbVie, Inc.

在研机构-

非在研机构

Abbott Laboratories

AbbVie, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C11H16N2O

InChIKeyYRVIKLBSVVNSHF-JTQLQIEISA-N

CAS号161417-03-4

查看全部结构式(2)

关联

11

项与 Pozanicline Hydrochloride 相关的临床试验

NCT01756053

/ Terminated临床2期IIT

A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit attempt (
4 days). The key cognitive domains include: working memory, sustained attention, and response inhibition.

开始日期2013-03-01

申办/合作机构

University of Pennsylvania

NCT00809510

/ Terminated临床2期

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

开始日期2009-01-01

申办/合作机构

Abbott Laboratories

NCT00686933

/ Completed临床2期

The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study M10-346

The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

开始日期2008-05-01

申办/合作机构

AbbVie, Inc.

100 项与 Pozanicline Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Pozanicline Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Pozanicline Hydrochloride 相关的专利（医药）

登录后查看更多信息

61

项与 Pozanicline Hydrochloride 相关的文献（医药）

2024-02-01·Powder Technology

The effects of humidity on the adhesion of pharmaceutical excipients to steel surfaces

作者: Beaudoin, Stephen ; Vogt, Andrew ; Cheah, WeiBin ; Main, Ethan ; Ketterhagen, William ; Jones, Olivia ; Park, Sarah ; Stevenson, Caralyn ; Sura, Isha ; Monroe, Jordan ; Zhang, Richael ; Nobbe, Briana ; Vazquez, Juan Manuel ; Capece, Maxx ; Upton, Josephine ; Roberts, Tyler

The adhesion between powders and surfaces is influenced by their topog.We investigate the relationships between the topog. on stainless steel, the humidity, and the adhesion of three pharmaceutical powders.These relationships are captured within 'effective' work of adhesion parameters tuned using the enhanced centrifuge method (ECM).The parameters describe the effects of the size, shape, humidity, and topog. on the adhesion.The powders' ability to nestle into features on the steel drove the work of adhesion.When the powders absorbed moisture, the balance of moisture-driven deformation and increased mass dictated the powder removal from the surface.The irregularly shaped hypromellose (HPMC) adhered more strongly to the stainless steel at low humidity than at high.The lactose monohydrate and ABT-089 showed the opposite behavior.The HPMC adhered more strongly to the rough steel than to the smooth or untreated steel.The lactose monohydrate and ABT-089 again showed the opposite behavior.

2021-04-01·American Journal of Medical Genetics Part B: Neuropsychiatric Genetics3区 · 医学

Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning

3区 · 医学

Article

作者: Díaz‐Otañez, Carlos Enrique ; Genis‐Mendoza, Alma Delia ; Flores, Gonzalo ; Nicolini, Humberto ; Monroy‐Jaramillo, Nancy ; García‐Dolores, Fernando ; López Armenta, Mauro ; Walss‐Bass, Consuelo ; Martínez‐Magaña, José Jaime ; Vázquez‐Roque, Rubén Antonio ; Fries, Gabriel Rodrigo ; Cabrera‐Mendoza, Brenda ; Fresno, Cristóbal

AbstractPatients with substance use disorders (SUD) are at high risk to die by suicide. So far, the neurobiology of the suicide‐SUD association has not been elucidated. This study aimed to identify potential pharmacological targets among hub genes from brain gene co‐expression networks of individuals with SUD in a suicidal and non‐suicidal context. Post‐mortem samples from the prefrontal cortex of 79 individuals were analyzed. Individuals were classified into the following groups: suicides with SUD (n = 28), suicides without SUD (n = 23), nonsuicides with SUD (n = 9), nonsuicides without SUD (n = 19). Gene expression profiles were evaluated with the Illumina HumanHT‐12 v4 array. Co‐expression networks were constructed in WGCNA using the differentially expressed genes found in the comparisons: (a) suicides with and without SUD and (b) nonsuicides with and without SUD. Hub genes were selected for drug‐gene interaction testing in the DGIdb database. Among drugs interacting with hub genes in suicides we found MAOA inhibitors and dextromethorphan. In the nonsuicide individuals, we found interactions with eglumegad and antipsychotics (olanzapine, clozapine, loxapine). Modafinil was found to interact with genes in both suicides and nonsuicides. These drugs represent possible candidate treatments for patients with SUD with and without suicidal behavior and their study in each context is encouraged.

2020-04-01·Psychopharmacology3区 · 医学

Dissociation of nicotinic α7 and α4/β2 sub-receptor agonists for enhancing learning and attentional filtering in nonhuman primates

3区 · 医学

Article

作者: Azimi, Marzyeh ; Womelsdorf, Thilo ; Oemisch, Mariann

RATIONALENicotinic acetylcholine receptors (nAChRs) modulate attention, memory, and higher executive functioning, but it is unclear how nACh sub-receptors mediate different mechanisms supporting these functions.OBJECTIVESWe investigated whether selective agonists for the alpha-7 nAChR versus the alpha-4/beta-2 nAChR have unique functional contributions for value learning and attentional filtering of distractors in the nonhuman primate.METHODSTwo adult rhesus macaque monkeys performed reversal learning following systemic administration of either the alpha-7 nAChR agonist PHA-543613 or the alpha-4/beta-2 nAChR agonist ABT-089 or a vehicle control. Behavioral analysis quantified performance accuracy, speed of processing, reversal learning speed, the control of distractor interference, perseveration tendencies, and motivation.RESULTSWe found that the alpha-7 nAChR agonist PHA-543613 enhanced the learning speed of feature values but did not modulate how salient distracting information was filtered from ongoing choice processes. In contrast, the selective alpha-4/beta-2 nAChR agonist ABT-089 did not affect learning speed but reduced distractibility. This dissociation was dose-dependent and evident in the absence of systematic changes in overall performance, reward intake, motivation to perform the task, perseveration tendencies, or reaction times.CONCLUSIONSThese results suggest nicotinic sub-receptor specific mechanisms consistent with (1) alpha-4/beta-2 nAChR specific amplification of cholinergic transients in prefrontal cortex linked to enhanced cue detection in light of interferences, and (2) alpha-7 nAChR specific activation prolonging cholinergic transients, which could facilitate subjects to follow-through with newly established attentional strategies when outcome contingencies change. These insights will be critical for developing function-specific drugs alleviating attention and learning deficits in neuro-psychiatric diseases.

100 项与 Pozanicline Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Pozanicline Hydrochloride	-	DB05458

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
注意缺陷障碍伴多动	临床2期	美国	Abbott Laboratories	2006-10-01
注意缺陷障碍伴多动	临床2期	美国	Abbott Laboratories	2006-10-01
阿尔茨海默症	临床2期	美国	Abbott Laboratories	2003-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01756053 (CTgov)	临床2期	尼古丁依赖	17	ABT-089 (ABT-089)	遞蓋壓網壓顧觸鏇襯衊(壓繭鹹簾蓋衊壓窪夢鹹) = 積鹹廠鹽鹽鹽製範遞壓獵窪齋餘願廠膚壓淵醖 (選餘獵簾糧鹹艱醖鹹餘, 鹹遞衊觸襯繭選膚蓋積 ~ 蓋鏇構襯餘選築淵觸製) 更多	-	2014-10-29
				Placebo (Placebo)	遞蓋壓網壓顧觸鏇襯衊(壓繭鹹簾蓋衊壓窪夢鹹) = 顧鬱淵簾遞憲選願選窪獵窪齋餘願廠膚壓淵醖 (選餘獵簾糧鹹艱醖鹹餘, 襯衊獵製壓構鬱鹹網鏇 ~ 憲膚廠積餘簾觸鹽蓋夢) 更多
NS59910 (WPC2013)	临床2期	-	-	Nicotine	壓夢遞範襯餘廠繭顧選(醖繭淵窪積餘獵膚鹹製) = 艱餘膚繭繭糧窪遞構淵選襯鹹網構簾蓋廠簾膚 (製壓襯範齋構蓋蓋壓夢 )	积极	2013-10-01
				Varenicline	壓夢遞範襯餘廠繭顧選(醖繭淵窪積餘獵膚鹹製) = 顧簾願襯繭鹽選淵鹹顧選襯鹹網構簾蓋廠簾膚 (製壓襯範齋構蓋蓋壓夢 )